FTIH of ECC4703 in Healthy Volunteers

July 2, 2024 updated by: Eccogene

A Randomized, Double-Blind, Placebo-Controlled, Single and Repeated Dose Escalation, FTIH Study to Investigate the Safety, Tolerability, PK and PD of ECC4703 in Healthy Volunteers and Participants With Treatment-Unnecessary LDL-C Under 160 mg/dL

This is a Phase 1, randomized, double-blind, placebo-controlled, single ascending dose and multiple ascending dose study of ECC4703 in healthy volunteers and participants with treatment unnecessary LDL-C under 160 mg/dL

Study Overview

Status

Status

Indicates the current recruitment status or the expanded access status.
Completed

Conditions

Conditions

The disease, disorder, syndrome, illness, or injury that is being studied. On ClinicalTrials.gov, conditions may also include other health-related issues, such as lifespan, quality of life, and health risks.

Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.

Detailed Description

This study will be conducted in two cohorts of Single Ascending Dose (SAD) with a dose range from 1mg to 400mg and in four cohorts of Multiple Ascending Dose (MAD) with a dose range of 40mg to 160mg to Investigate the Safety, Tolerability, PK, and PD of ECC4703 in Healthy Volunteers and Participants with Treatment Unnecessary LDL-C under 160 mg/dL

Study Type

Study Type

Describes the nature of a clinical study. Study types include interventional studies (also called clinical trials), observational studies (including patient registries), and expanded access.
Interventional

Enrollment (Actual)

Enrollment

The number of participants in a clinical study. The "anticipated" enrollment is the target number of participants that the researchers need for the study.
75

Phase

Phase

The stage of a clinical trial studying a drug or biological product, based on definitions developed by the U.S. Food and Drug Administration (FDA). The phase is based on the study's objective, the number of participants, and other characteristics. There are five phases: Early Phase 1 (formerly listed as Phase 0), Phase 1, Phase 2, Phase 3, and Phase 4. Not Applicable is used to describe trials without FDA-defined phases, including trials of devices or behavioral interventions.
  • Early Phase 1

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Contact

The name and contact information for the person who can answer enrollment questions for a clinical study. Each location where the study is being conducted may also have a specific contact, who may be better able to answer those questions.

Study Locations

  • United States
    • Nevada
      • Las Vegas, Nevada, United States, 89113
        • Eccogene Investigational Site

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Eligibility Criteria

The key requirements that people who want to participate in a clinical study must meet or the characteristics they must have. Eligibility criteria consist of both inclusion criteria (which are required for a person to participate in the study) and exclusion criteria (which prevent a person from participating). Types of eligibility criteria include whether a study accepts healthy volunteers, has age or age group requirements, or is limited by sex.

Ages Eligible for Study

18 years to 65 years (Adult, Older Adult)

Accepts Healthy Volunteers

Yes

Description

Inclusion Criteria:

  • Healthy male and female participants of any ethnic origin
  • Age of 18 to 65 years
  • BMI of 18.0 to 32.0 kg/m2
  • Female participants who are postmenopausal, confirmed by FSH test, or surgically sterile, confirmed by medical documentation, or if they are of child bearing potential agree to use at least 1 highly effective method of contraception and 1 additional effective method at the same time, or agree to practice true abstinence
  • Male participants agree to use contraception, or agree to practice true abstinence
  • No clinically significant findings in physical examination, 12-lead electrocardiogram (ECG), vital sign measurements, laboratory tests, or medical/psychiatric history
  • Not taking any medication on a regular basis
  • Able to understand and sign and date informed consent

Additional Inclusion Criteria for Part 2 (MAD) Cohorts B2 to B4

  • Fasting LDL-C ≥ 100 mg/dL and ≤ 159 mg/dL at screening
  • Not eligible for lipid-lowering therapy (such as statin) as decided by the qualified clinician at screening based on <2019 ACC/AHA Guidelines on the Primary Prevention of Cardiovascular Disease>
  • Hemoglobin A1c (HbA1c) ≤ 6.5%.

Exclusion Criteria:

  • Females who are pregnant including a positive result of pregnancy test, planning to become pregnant, or breastfeeding.
  • History of febrile illness or evidence of active infection within 14 days prior to the first dose of study;
  • Use of any concomitant medication
  • History of drug abuse or alcohol abuse within the past 5 years;
  • Regular use of tobacco, nicotine or tobacco products within the past 6 months of the study ;
  • Unwilling to abstain from alcohol containing products and/or xanthine/caffeine containing products, including any food and beverages, within 48 h prior to the first dose of study drug;
  • Concomitant participation in any investigational study of any nature
  • Blood loss of non-physiological reasons ≥ 200 ml (i.e. trauma, blood collection, blood donation) within 2 months prior to the first dose of study drug, or plan to donate blood during this trial and within 1 month after the last dosing;
  • Abnormal renal function estimated glomerular filtration rate (eGFR) < 90 mL/min/1.73m2
  • Currently diagnosed type 2 diabetes mellitus (T2DM) or has history of T2DM.
  • Significant allergic reaction to active ingredients or excipients of the study drug.
  • Any clinically significant abnormal findings in the participant's physical examination, laboratory tests, pregnancy test, urine drug screen, alcohol test, or medical history which in the opinion of the Investigator would prevent the participants from participating in the study.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Triple

Arms and Interventions

Participant Group / Arm

Participant Group / Arm

A group or subgroup of participants in a clinical trial that receives a specific intervention/treatment, or no intervention, according to the trial's protocol.
Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.
Placebo Comparator: SAD Cohorts 1 to 2: Participants receiving Placebo
Participants in each SAD cohort will be randomized to receive placebo
Drug: Placebo
Matching Placebo will be administered as oral capsules. Matching Placebo will be given orally during each dosing day.
Experimental: SAD Cohorts 1 to 2: Participants receiving ECC4703
Participants in each SAD cohort will be randomized to receive up to 4 escalating doses (1 mg, 4 mg, 12 mg, 32 mg, 80 mg, 160 mg, 320 mg or 400 mg).
Drug: ECC4703
ECC4703 will be administered as 1 mg, 10 mg and 40 mg capsules. ECC4703 will be administered as oral capsules during each dosing day.
Placebo Comparator: MAD Cohorts 1 to 4: Participants receiving Placebo
Participants will be randomized to receive a once-daily dose of placebo for 14 days.
Drug: Placebo
Matching Placebo will be administered as oral capsules. Matching Placebo will be given orally during each dosing day.
Experimental: MAD Cohorts 1 to 4: Participants receiving ECC4703
Participants will be randomized to receive a once-daily dose of 1 of 3 escalating doses (40 mg, 80 mg, or 160 mg) for 14 days.
Drug: ECC4703
ECC4703 will be administered as 1 mg, 10 mg and 40 mg capsules. ECC4703 will be administered as oral capsules during each dosing day.

What is the study measuring?

Primary Outcome Measures

Primary Outcome Measures

In a clinical study's protocol, the planned outcome measure that is the most important for evaluating the effect of an intervention/treatment. Most clinical studies have one primary outcome measure, but some have more than one.
Outcome Measure
Measure Description
Time Frame
Number of participants with adverse events, with abnormal laboratory test results, abnormal ECGs, abnormal vital signs, and abnormal physical examinations
Time Frame: SAD: Up to 8 days and MAD: Up to 21 days
Safety Assessment evaluated through adverse events, laboratory evaluations, vital signs, ECGs, and physical examination.
SAD: Up to 8 days and MAD: Up to 21 days

Secondary Outcome Measures

Secondary Outcome Measures

In a clinical study's protocol, a planned outcome measure that is not as important as the primary outcome measure for evaluating the effect of an intervention but is still of interest. Most clinical studies have more than one secondary outcome measure.
Outcome Measure
Measure Description
Time Frame
Pharmacokinetic Parameters: AUC0-24
Time Frame: SAD: Up to Day 8 and MAD: Up to Day 21.
AUC from time 0 to 24 hour dosing interval
SAD: Up to Day 8 and MAD: Up to Day 21.
Pharmacokinetic Parameters: AUC0-tlast
Time Frame: SAD: Up to Day 8
AUC from time 0 to the time of last quantifiable non-zero concentration
SAD: Up to Day 8
Pharmacokinetic Parameters: AUC0-tau
Time Frame: MAD: Up to Day 21.
AUC over a dosing interval from time 0 to time of last quantifiable concentration
MAD: Up to Day 21.
Pharmacokinetic Parameters: AUC0-infinity
Time Frame: SAD: Up to Day 8
AUC from time 0 extrapolated to infinity
SAD: Up to Day 8
Pharmacokinetic Parameters: Cmax
Time Frame: SAD: Up to Day 8 and MAD: Up to Day 21.
Maximum observed plasma concentration
SAD: Up to Day 8 and MAD: Up to Day 21.
Pharmacokinetic Parameters: C24
Time Frame: SAD: Up to Day 8 and MAD: Up to Day 21.
Observed concentration at 24 hours post dose
SAD: Up to Day 8 and MAD: Up to Day 21.
Pharmacokinetic Parameters: Ctau
Time Frame: MAD: Up to Day 21.
Observed concentration at the end of the dosing interval
MAD: Up to Day 21.
Pharmacokinetic Parameters: tmax
Time Frame: SAD: Up to Day 8 and MAD: Up to Day 21.
Time of the maximum observed plasma concentration
SAD: Up to Day 8 and MAD: Up to Day 21.
Pharmacokinetic Parameters: tlag
Time Frame: SAD: Up to Day 8 and MAD: Up to Day 21.
Lag time (time delay between dosing and first observed plasma concentration)
SAD: Up to Day 8 and MAD: Up to Day 21.
Pharmacokinetic Parameters: t1/2
Time Frame: SAD: Up to Day 8 and MAD: Up to Day 21.
Apparent terminal elimination half-life
SAD: Up to Day 8 and MAD: Up to Day 21.
Pharmacokinetic Parameters: Clast
Time Frame: SAD: Up to Day 8
Last measurable non-zero concentration
SAD: Up to Day 8
Pharmacokinetic Parameters: tlast
Time Frame: SAD: Up to Day 8
Time of last measurable non-zero concentration
SAD: Up to Day 8
Pharmacokinetic Parameters: CL/F
Time Frame: SAD: Up to Day 8 and MAD: Up to Day 21.
Apparent Clearance
SAD: Up to Day 8 and MAD: Up to Day 21.
Pharmacodynamic assessment: LDL-C
Time Frame: SAD: Up to Day 8
Measurement of Low Density Lipoprotein Cholesterol
SAD: Up to Day 8
Pharmacodynamic assessment: HDL-C
Time Frame: MAD: Up to Day 21.
Measurement of High Density Lipoprotein Cholesterol
MAD: Up to Day 21.
Pharmacodynamic assessment: TG
Time Frame: MAD: Up to Day 21.
Measurement of Triglycerides
MAD: Up to Day 21.
Pharmacodynamic assessment: TC
Time Frame: MAD: Up to Day 21.
Measurement of Total Cholesterol
MAD: Up to Day 21.
Pharmacodynamic assessment: LDL
Time Frame: MAD: Up to Day 21.
Measurement of Low Density Lipoprotein
MAD: Up to Day 21.
Pharmacodynamic assessment: VLDL
Time Frame: MAD: Up to Day 21.
Measurement of Very Low Density Lipoprotein
MAD: Up to Day 21.
Pharmacodynamic assessment: ApoB
Time Frame: SAD: Up to Day 8 and MAD: Up to Day 21.
Measurement of Apolipoprotein B
SAD: Up to Day 8 and MAD: Up to Day 21.
Pharmacodynamic assessment: Lp(a)
Time Frame: MAD: Up to Day 21.
Measurement of Lipoprotein (a)
MAD: Up to Day 21.
Pharmacodynamic assessment: Glucose
Time Frame: MAD: Up to Day 21.
Measurement of Glucose
MAD: Up to Day 21.
Pharmacodynamic assessment: Serum Insulin
Time Frame: MAD: Up to Day 21.
Measurement of Serum Insulin
MAD: Up to Day 21.
Thyroid function assessment: TT3
Time Frame: SAD: Up to Day 8 and MAD: Up to Day 21.
Measurement of Total Triiodothyronine
SAD: Up to Day 8 and MAD: Up to Day 21.
Thyroid function assessment: FT3
Time Frame: SAD: Up to Day 8 and MAD: Up to Day 21.
Measurement of Free Triiodothyronine
SAD: Up to Day 8 and MAD: Up to Day 21.
Thyroid function assessment: TT4
Time Frame: SAD: Up to Day 8 and MAD: Up to Day 21.
Measurement of Total Thyroxine
SAD: Up to Day 8 and MAD: Up to Day 21.
Thyroid function assessment: FT4
Time Frame: SAD: Up to Day 8 and MAD: Up to Day 21.
Measurement of Free Thyroxine
SAD: Up to Day 8 and MAD: Up to Day 21.
Thyroid function assessment: TSH
Time Frame: SAD: Up to Day 8 and MAD: Up to Day 21.
Measurement of Thyroid Stimulating Hormone
SAD: Up to Day 8 and MAD: Up to Day 21.

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Sponsor

The organization or person who initiates the study and who has authority and control over the study.
Eccogene

Investigators

Investigators

A researcher involved in a clinical study. Related terms include site principal investigator, site sub-investigator, study chair, study director, and study principal investigator.
  • Study Director: Eccogene, Eccogene Clinical Trials

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

Study Start

The actual date on which the first participant was enrolled in a clinical study. The "anticipated" study start date is the date that the researchers think will be the study start date.
August 16, 2022

Primary Completion (Actual)

Primary Completion

The date on which the last participant in a clinical study was examined or received an intervention to collect final data for the primary outcome measure. Whether the clinical study ended according to the protocol or was terminated does not affect this date. For clinical studies with more than one primary outcome measure with different completion dates, this term refers to the date on which data collection is completed for all the primary outcome measures. The "anticipated" primary completion date is the date that the researchers think will be the primary completion date for the study.
October 26, 2023

Study Completion (Actual)

Study Completion

The date on which the last participant in a clinical study was examined or received an intervention/treatment to collect final data for the primary outcome measures, secondary outcome measures, and adverse events (that is, the last participant's last visit). The "anticipated" study completion date is the date that the researchers think will be the study completion date.
October 26, 2023

Study Registration Dates

First Submitted

First Submitted

The date on which the study sponsor or investigator first submitted a study record to ClinicalTrials.gov. There is typically a delay of a few days between the first submitted date and the record's availability on ClinicalTrials.gov (the first posted date).
September 13, 2022

First Submitted That Met QC Criteria

First Submitted That Met QC Criteria

The date on which the study sponsor or investigator first submits a study record that is consistent with National Library of Medicine (NLM) quality control (QC) review criteria. The sponsor or investigator may need to revise and submit a study record one or more times before NLM's QC review criteria are met. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
September 20, 2022

First Posted (Actual)

First Posted

The date on which the study record was first available on ClinicalTrials.gov after National Library of Medicine (NLM) quality control (QC) review has concluded. There is typically a delay of a few days between the date the study sponsor or investigator submitted the study record and the first posted date.
September 23, 2022

Study Record Updates

Last Update Posted (Actual)

Last Update Posted

The most recent date on which changes to a study record were made available on ClinicalTrials.gov. There may be a delay between when the changes were submitted to ClinicalTrials.gov by the study's sponsor or investigator (the last update submitted date) and the last update posted date.
July 5, 2024

Last Update Submitted That Met QC Criteria

Last Update Submitted That Met QC Criteria

The most recent date on which the study sponsor or investigator submitted changes to a study record that are consistent with National Library of Medicine (NLM) quality control (QC) review criteria. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
July 2, 2024

Last Verified

Last Verified

The most recent date on which the study sponsor or investigator confirmed the information about a clinical study on ClinicalTrials.gov as accurate and current. If a study with a recruitment status of recruiting; not yet recruiting; or active, not recruiting has not been confirmed within the past 2 years, the study's recruitment status is shown as unknown.
July 1, 2024

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

Other Study ID Numbers

Identifiers or ID numbers other than the NCT number that are assigned to a clinical study by the study's sponsor, funders, or others. These numbers may include unique identifiers from other trial registries and National Institutes of Health grant numbers.
  • EC0002

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

Yes

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Cookie Settings

We use cookies to ensure that we give you the best experience on our website. For more details carefully read our Privacy and Cookies Policy. ...>>>You can change your preferences or withdraw your consent at any time by deleting the cookies from your website or computer as described in the policy. Please accept it and choose your preferences by ticking the corresponding boxes in the "Manage Settings" section below. Please carefully read our Terms of Service before you proceed with using any part of this website.
«Manage Settings